![]() | |
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C20H25ClN2O |
Molar mass | 344.88 g·mol−1 |
3D model ( JSmol) | |
| |
|
ADX-71149, also known as JNJ-40411813 and JNJ-mGluR2-PAM, is a selective positive allosteric modulator of the mGlu2 receptor. [1] [2] [3] It is being studied by Addex Therapeutics and Janssen Pharmaceuticals for the treatment of schizophrenia. [4] It was also researched by these companies for the treatment of anxious depression ( major depressive disorder with anxiety symptoms), [5] but although some efficacy was observed in clinical trials, it was not enough to warrant further development for this indication. [6] As of 2015 [update], ADX-71149 is in phase II clinical trials for schizophrenia. [4]
![]() | |
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C20H25ClN2O |
Molar mass | 344.88 g·mol−1 |
3D model ( JSmol) | |
| |
|
ADX-71149, also known as JNJ-40411813 and JNJ-mGluR2-PAM, is a selective positive allosteric modulator of the mGlu2 receptor. [1] [2] [3] It is being studied by Addex Therapeutics and Janssen Pharmaceuticals for the treatment of schizophrenia. [4] It was also researched by these companies for the treatment of anxious depression ( major depressive disorder with anxiety symptoms), [5] but although some efficacy was observed in clinical trials, it was not enough to warrant further development for this indication. [6] As of 2015 [update], ADX-71149 is in phase II clinical trials for schizophrenia. [4]